Arctic Bioscience – More than 75% recruited in the phase IIb HeROPA clinical trial
With reference to the Q3 update from November 2[nd] 2023 which reported more than 50% recruited patients to the phase IIb clinical trial HeROPA, Arctic Bioscience is pleased to report that we have now recruited more than 75% of the patients required for the trial.The HeROPA phase IIb clinical trial of HRO350 - a novel, oral drug candidate for the treatment of mild-to-moderate psoriasis - is ongoing in 5 countries in Europe; UK, Germany, Poland, Finland and Norway. As planned, recruitment speed has increased throughout fall as new clinics have been activated. Recruitment is going